Skip to main content
SpringerLink
Log in

Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.

  • Letter to the Editor
  • Published:
Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Triggiani L, Mazzola R, Tomasini D, et al. Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Med Oncol. 2021;38(6):72.

    Article  CAS  Google Scholar 

  2. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.

    Article  CAS  Google Scholar 

  3. Onal C, Ozyigit G, Guler OC, Hurmuz P, Torun N, Tuncel M, et al. Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients. Radiother Oncol. 2020;151:222–7.

    Article  CAS  Google Scholar 

  4. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17. https://doi.org/10.1016/j.eururo.2019.01.049.

    Article  PubMed  Google Scholar 

  5. Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12. https://doi.org/10.1016/j.eururo.2015.07.004.

    Article  PubMed  Google Scholar 

  6. Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, et al. Treatment outcomes of metastasis-directed treatment using (68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09–002). Strahlenther Onkol. 2020;196(11):1034–43. https://doi.org/10.1007/s00066-020-01660-6.

    Article  PubMed  Google Scholar 

  7. Vilela RA, Navarro NF, Faria ET, Ferreira EB, Ruzza RZ, Gadia R, et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review. J Med Imaging Radiat Oncol. 2018;62(5):692–706. https://doi.org/10.1111/1754-9485.12747.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Centre, Baskent University Faculty of Medicine, 01120, Adana, Turkey

    Cem Onal & Ozan Cem Guler

  2. Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey

    Ezgi Oymak

Authors
  1. Cem Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ezgi Oymak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozan Cem Guler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cem Onal.

Ethics declarations

Conflict of interest

All authors declare no conflicts of interest related to this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onal, C., Oymak, E. & Guler, O.C. Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.. Med Oncol 38, 81 (2021). https://doi.org/10.1007/s12032-021-01528-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-021-01528-4

Search

Navigation